Evidence map›Paper›PMID 26074740›Full record

ReviewCurrent neuropharmacology2015

Synthetic cathinones: a new public health problem.

Laurent Karila, Bruno Megarbane, Olivier Cottencin, Michel Lejoyeux

Open access · greenAbstract readReview
In one paragraph

Review in Current neuropharmacology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
55citing papers in PubMed, 2 pooled it
10.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

55 citing papers in PubMed, 2 syntheses or guidelines pooled it, 248 citations in OpenAlex.

  1. Pooled it
  2. Synthetic Cathinones and Neurotoxicity Risks: A Systematic Review.International journal of molecular sciences · 2023
    Pooled it
  3. Trial
  4. 4,4'-DMARFrontiers in cardiovascular medicine · 2026
    Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Review
  15. Review
  16. Review
  17. Article
  18. An updated review on synthetic cathinones.Archives of toxicology · 2021
    Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 4 institutions in 1 country.

Laurent KarilaAddiction Research and Treatment Center, Paul Brousse Hospital, Paris-Sud University, Villejuif 94800, France; CEA-INSERM, Orsay, France;
Bruno MegarbaneInserm, U1144, Paris, F-75006, France ; Department of Medical and Toxicological Critical Care, Lariboisière Hospital, Paris-Diderot University, 75010 Paris, France;
Olivier CottencinDepartment of Psychiatry and Addictology, CHRU Lille, France;
Michel LejoyeuxDepartment of Psychiatry and Addictology, Bichat Hospital, Paris-Diderot University, Paris, France;
Centre Hospitalier Universitaire de Lille · FRCommissariat à l'Énergie Atomique et aux Énergies Alternatives · FRHôpital Bichat-Claude-Bernard · FRHôpital Lariboisière · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

New psychoactive substances (NPS) have completely modified the drug scene and the current landscape of addiction. Synthetic substances, such as substituted or synthetic cathinones, also known as « legal highs », are often produced and used to mimic the effects of controlled drugs such as cocaine, methylenedioxymethamphetamine (MDMA, ecstasy), and methamphetamine. The overwhelming majority of synthetic cathinones are produced in China and South East Asian countries. The Internet has emerged as the new marketplace for NPS, playing a major role in providing information on acquisition, synthesis, extraction, identification, and substance use. All these compounds are intentionally mislabeled and sold on-line under slang terms such as bath salts, plant food, plant feeders and research chemicals. They are sometimes labeled « not for human use » or « not tested for hazards or toxicity ». The rapid spread of NPS forces member countries of the European Union to adapt their response to the potential new dangers that may cause. To date, not only health actors but also the general public need to be clearly informed and aware of dangers resulting from NPS spread and use. Here, we review the major clinical effects of synthetic cathinones to highlight their impact on public health. A literature search was conducted from 2009 to 2014 based on PubMed, Google Scholar, Erowid, and governmental websites, using the following keywords alone or in combination: "new psychoactive substances", "synthetic cathinones", "substituted cathinones", "mephedrone", "methylone", "MDPV", "4-MEC", "addiction", and "substance use disorder".

Indexed as

AlkaloidsDesigner DrugsDrug UsersHumansIllicit DrugsPsychotropic DrugsSubstance-Related DisordersAlkaloidscathinoneDesigner DrugsIllicit DrugsPsychotropic Drugs4-MECAddictionMDPVmephedronemethylonenew psychoactive substancessubstance use disordersubstituted cathinonessynthetic cathinones

Identifiers

PMID26074740
PMCPMC4462036
OpenAlexW2328803154

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.